E
Editas Medicine
Cambridge, United States
Founded 2013 NASDAQ: EDIT
Gene Therapy Delivery Cell Therapy Nano DNA Nanotechnology Nano-Bio Protein Engineering Nanosequencing
About
Genome editing company using CRISPR with lipid nanoparticle delivery systems
Company Details
- Type
- public
- Employees
- 400+
- Funding
- Public
Key Products
- EDIT-101
- EDIT-301